Inclusion Criteria:

          -  Ph+ ALL with p190 or p210 detectable and measurable (at least 10-4 x10000 ABL) after
             at least 3 months of any therapy, or the failure of at least 2 TKI.

          -  Ph- ALL with detectable and measurable IG specific transcript after at least 2 courses
             of previous therapy.

          -  Age ≥ 18 years old.

          -  ECOG ≤ 2.

        Exclusion Criteria:

          -  More than 5% of BM blasts.

          -  WHO performance status ≤ 50% (Karnofsky) or ≥ 3 (ECOG).

          -  Active HBV or HCV hepatitis, or AST/ALT ≥ 2.5 x ULN and bilirubine ≥ 1.5 x ULN.

          -  Evidence of liver fibrosis, portal hypertension or other clinically relevant liver
             abnormalities at screening liver ultrasonography.

          -  History of alcohol abuse.

          -  Burkitt lymphoma and active CNS leukemia. Patients with previuos neurological
             toxicitiy as well co-morbidity will be carefully evaluated for enrolment.

          -  Ongoing or active infections.

          -  Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL). Clinically significant,
             uncontrolled, or active cardiovascular disease.

          -  Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg).
             Patients with hypertension should be under treatment on study entry to effect blood
             pressure control.

          -  Creatinine level > 2.5mg/dl or Glomerular Filtration Rate (GFR) < 20 ml/min or
             proteinuria > 3.5 g/day.

          -  Documented inherited protrombotic disorders

          -  Patients who have received any investigational drug ≤ 4 weeks.

          -  Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or
             who have not recovered from side effects of such therapy.

          -  Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention or with a life expectancy due to
             other malignancy <6 months.

          -  Patients that have received Inotuzumab or Anti CD22 directed therapies before

          -  Patients with known hereditary coagulopathy

          -  Patient that received during their life diagnosis of VOD or had ongoing VOD

          -  Patients who are pregnant or breastfeeding and adults of reproductive potential not
             employing an effective method of birth control (women of childbearing potential must
             have a negative serum pregnancy test within 48 hrs prior to administration of
             induction therapy). Postmenopausal women must be amenorrheic for at least 12 months to
             be considered of non-childbearing potential. Male and female patients must agree to
             employ an effective barrier method of birth control throughout the study and for up to
             4 months following discontinuation of study drugs.

          -  Patients unwilling or unable to comply with the protocol.